ropinirole has been researched along with Parkinson Disease, Secondary in 7 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rotenone is a neurotoxin that selectively destroys dopaminergic neurons, leading to PD-like symptoms." | 1.56 | Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats. ( Raj, K; Sharma, S; Singh, S, 2020) |
| "They display some memory deficits as in human Parkinson's desease." | 1.31 | The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome. ( Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM, 2001) |
| "Ropinirole did not cause marked stereotypies." | 1.28 | Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. ( Costall, B; Domeney, AM; Eden, RJ; Gerrard, PA; Harvey, CA; Kelly, ME; Naylor, RJ; Owen, DA; Wright, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, S | 1 |
| Raj, K | 1 |
| Singh, S | 1 |
| Wang, Y | 1 |
| Bouabid, S | 1 |
| Darvas, M | 1 |
| Zhou, FM | 1 |
| Carta, AR | 1 |
| Frau, L | 1 |
| Pinna, A | 1 |
| Morelli, M | 1 |
| Thomas, A | 1 |
| Bonanni, L | 1 |
| Di Iorio, A | 1 |
| Varanese, S | 1 |
| Anzellotti, F | 1 |
| D'Andreagiovanni, A | 1 |
| Stocchi, F | 1 |
| Onofrj, M | 1 |
| Pearce, RK | 1 |
| Banerji, T | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Callizot, N | 1 |
| Guénet, JL | 1 |
| Baillet, C | 1 |
| Warter, JM | 1 |
| Poindron, P | 1 |
| Eden, RJ | 1 |
| Costall, B | 1 |
| Domeney, AM | 1 |
| Gerrard, PA | 1 |
| Harvey, CA | 1 |
| Kelly, ME | 1 |
| Naylor, RJ | 1 |
| Owen, DA | 1 |
| Wright, A | 1 |
1 trial available for ropinirole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.
Topics: Benzothiazoles; Dopamine Agonists; Double-Blind Method; Endpoint Determination; Female; Humans; Indo | 2006 |
6 other studies available for ropinirole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats.
Topics: Alkaloids; Benzodioxoles; Corpus Striatum; Dietary Supplements; Drug Synergism; Electron Transport C | 2020 |
The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Homeodomain Proteins; Indoles; Male; Mice; Mice | 2020 |
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2010 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithr | 1998 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Anima | 2001 |
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Animals; Antiparkinson Agents; Bloo | 1991 |